Search Results

You are looking at 1 - 3 of 3 items for

  • Author: Liqin Pan x
Clear All Modify Search
Guoquan Zhu Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Guoquan Zhu in
Google Scholar
PubMed
Close
,
Yuying Deng Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Yuying Deng in
Google Scholar
PubMed
Close
,
Liqin Pan Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Liqin Pan in
Google Scholar
PubMed
Close
,
Wei Ouyang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Wei Ouyang in
Google Scholar
PubMed
Close
,
Huijuan Feng Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Huijuan Feng in
Google Scholar
PubMed
Close
,
Juqing Wu Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Juqing Wu in
Google Scholar
PubMed
Close
,
Pan Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Pan Chen in
Google Scholar
PubMed
Close
,
Jing Wang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Jing Wang in
Google Scholar
PubMed
Close
,
Yanying Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Yanying Chen in
Google Scholar
PubMed
Close
, and
Jiaxin Luo Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Search for other papers by Jiaxin Luo in
Google Scholar
PubMed
Close

The goal of this study was to explore the relationship of the BRAFV600E mutation with clinicopathologic factors and evaluate the effect of radioactive iodine (RAI) therapy in a large group of intermediate- and high-risk papillary thyroid cancer (PTC) patients with the BRAFV600E mutation and without distant metastases. We collected data for PTC patients who underwent total or near-total thyroidectomy and RAI treatment in our hospital from January 2014–December 2017. There were 1220 PTC patients who met the criteria, and the BRAFV600E mutation was observed in 979 of them (80.2%). Multivariate analysis identified that the BRAFV600E mutation remained independently associated with age at diagnosis, and bilaterality (OR = 1.023, 95% CI = 1.012–1.039, P < 0.001; OR = 1.685, 95% CI = 1.213–2.341, P = 0.002, respectively). In addition, the patients with bilateral PTCs had a higher prevalence of extrathyroid invasion, capsular invasion and fusion of metastatic lymph nodes than the unilateral PTC patients. The response to RAI therapy was evaluated in both the entire series and the patients with a high recurrence risk; no significant difference was discerned between the BRAFV600E mutation and the wild-type groups (P = 0.237 and P = 0.498, respectively). To summarize, our results confirmed that PTC patients with the BRAFV600E mutation exhibit more aggressive characteristics. In addition, the patients with bilateral PTC have a higher incidence of extrathyroid invasion. Moreover, BRAFV600E mutation PTC patients did not show a poorer clinical response after postsurgical RAI therapy, suggesting that RAI therapy may improve the general clinical outcome of these patients.

Open access
Pan Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Pan Chen in
Google Scholar
PubMed
Close
,
Liqin Pan Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Liqin Pan in
Google Scholar
PubMed
Close
,
Wensi Huang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Wensi Huang in
Google Scholar
PubMed
Close
,
Huijuan Feng Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Huijuan Feng in
Google Scholar
PubMed
Close
,
Wei Ouyang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Wei Ouyang in
Google Scholar
PubMed
Close
,
Juqing Wu Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Juqing Wu in
Google Scholar
PubMed
Close
,
Jing Wang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Jing Wang in
Google Scholar
PubMed
Close
,
Yuying Deng Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Yuying Deng in
Google Scholar
PubMed
Close
,
Jiaxin Luo Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Jiaxin Luo in
Google Scholar
PubMed
Close
, and
Yanying Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Yanying Chen in
Google Scholar
PubMed
Close

Objective

To evaluate the relationship between the BRAF V600E mutation in lymph node metastasis (LNM) and its invasive characteristics in papillary thyroid cancer (PTC).

Material and methods

A total of 373 PTC patients were enrolled in this study conducted at Zhujiang Hospital of Southern Medical University between January 2017 and December 2018. PTCs with cervical lymph node metastases were verified pathohistologically, and primary tumors and LNM were examined for the BRAF V600E mutation. Patients were excluded from the study if the BRAF V600E mutation was examined only in primary tumors or only in LNM.

Results

Of the 373 patients examined, BRAF V600E mutation frequency in primary tumors was slightly higher than in LNM (81.5% vs 78.0%, P = 0.000), the intra-class correlation coefficient (ICC) was 0.865 (95% CI 0.835–0.890). The BRAF V600E mutation in both primary tumor and LNM negatively correlated with the size of the largest metastatic focus of LNM (Odds ratio, OR = 0.297, 95% CI 0.143–0.616, P = 0.001; OR = 0.242, 95% CI 0.119–0.492, P = 0.000, respectively). There was no relationship between BRAF V600E mutation in LNM and the number, extranodal extension or stage of LNM (P > 0.05).

Conclusion

The BRAF V600E mutation in LNM may not be related to the invasive characteristics of LNM in PTC.

Open access
Jiaxin Luo Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Jiaxin Luo in
Google Scholar
PubMed
Close
,
Weili Yin Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Weili Yin in
Google Scholar
PubMed
Close
,
Qiuxia Lin The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Qiuxia Lin in
Google Scholar
PubMed
Close
,
Juqing Wu Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Juqing Wu in
Google Scholar
PubMed
Close
,
Pan Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Pan Chen in
Google Scholar
PubMed
Close
,
Yuanna Ling Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Yuanna Ling in
Google Scholar
PubMed
Close
,
Jing Wang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Jing Wang in
Google Scholar
PubMed
Close
,
Zhen Li Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Zhen Li in
Google Scholar
PubMed
Close
,
Liqin Pan Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Liqin Pan in
Google Scholar
PubMed
Close
,
Yanying Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Yanying Chen in
Google Scholar
PubMed
Close
,
Wei Ouyang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Wei Ouyang in
Google Scholar
PubMed
Close
, and
Huijuan Feng Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Huijuan Feng in
Google Scholar
PubMed
Close

To evaluate the locoregional progression-free survival (LPFS) of bone metastatic lesions from differentiated thyroid cancer (DTC) after radioiodine therapy (RAIT) and to define its influencing factors, we performed a retrospective cohort analysis of 89 patients with bone metastases from DTC who received RAIT in our department over a 17-year period. The median follow-up time was calculated using the reverse Kaplan–Meier method. The log-rank test and a multivariate Cox proportional hazards regression model were performed in the analysis of prognostic indicators for LPFS. In this research, the median follow-up time for all patients was 47 (95% CI, 35.752–58.248) months, and that for patients with no progression was 42 months. The longest follow-up time was 109 months. The median LPFS time was 58 (95% CI, 32.602–83.398) months, and the 3- and 5-year LPFS probabilities were 57.8 and 45.1%, respectively. Multivariate analysis revealed bone structural changes as an independent risk factor for LPFS (P= 0.004; hazard ratio, 49.216; 95% CI, 3.558–680.704). Furthermore, the non–total-lesion uptake subgroup presented a worse LPFS than the total-lesion uptake subgroup in patients with structural bone lesions (P = 0.027). RAIT can improve the LPFS of radioiodine-avid bone metastases from DTC, especially those without bone structural changes.

Open access